Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
about
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerTrial watch - inhibiting PARP enzymes for anticancer therapyTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Molecular classification of gastric cancer: Towards a pathway-driven targeted therapyCIViC databaseTargeting the RAS oncogene.The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.Therapeutic targeting of cancers with loss of PTEN function.Maximising the potential of AKT inhibitors as anti-cancer treatmentsChemoresistance and targeted therapies in ovarian and endometrial cancersAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorWnt7a Inhibits IL-1β Induced Catabolic Gene Expression and Prevents Articular Cartilage Damage in Experimental OsteoarthritisIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathwaysAccurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsGenetically engineered mouse models of PI3K signaling in breast cancer.Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.The Akt-mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload.The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse modelsNext-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.AKT signaling in ERBB2-amplified breast cancer.A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumorsRecurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivityElevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentThe hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growthTargeting the PI3-kinase/Akt/mTOR signaling pathway.Targeting the PI3K-AKT-mTOR signaling network in cancer.
P2860
Q26744721-D3FF8CB8-68A5-4425-AE09-BA4396B18522Q26745673-13C3AD91-923A-4649-8FC0-0364667BB05CQ26775940-7F97D56C-EAB0-42D7-B1E5-2B00A5C843E6Q26798420-063D34DC-FDE2-4C65-9433-42C35DD5D9E7Q27612411-EEFD9D37-11A0-488C-86D9-D75FE6931A98Q27687198-80889059-729D-4610-A8B1-7156DADF921EQ27852562-90FFAF9C-40CD-4EE4-B90E-5F66CA7988D5Q27852764-7874E6E7-D2A4-436A-A679-ADCA26E1DAA5Q28072254-93C31E52-6D04-4113-A88F-8C231BA72C74Q28073246-0A8A80DD-8A2E-406C-BBBF-2F5DA8E6F8AEQ28080599-2C1FE0F0-8E50-4FE6-A611-23023331B65FQ28540161-7650BFA6-A9D9-4785-9CA8-0D2399E8E5ADQ29248654-46459889-2AD9-4D72-B0F8-0D646238A353Q33601377-BAAC2D38-F1DC-4BAA-AAB0-EC2655D4B3A5Q33623156-41FE7A47-C96D-4005-924C-BBF38236B91DQ33637346-E2498F92-BBA2-46D7-89BA-C249CD08E4BCQ33764664-27EE67C6-5BD0-4916-BEE7-6A66147276FBQ34332175-F66474BE-89B3-4F77-AB73-A2702319816EQ34365942-13804539-894A-49CD-8E65-9490223104DAQ34595624-063DEC66-715A-471C-BF7B-BEFE5E7EC4C7Q35000243-3876F55E-3D61-4C42-A5AD-481ABEAD27B8Q35382353-1809F4F1-34F8-48B8-A083-73AAFA172A74Q35775241-BB467310-732F-4F83-BB60-EB6B7A31B36DQ35849919-7C4BB259-343B-4D12-B9B5-0FB6781A2CA6Q35980053-7D490BB2-116B-4626-A0FA-F55E110E634BQ36101969-8EF7F49D-508B-4719-96B3-D79FFBB42628Q36227198-2C483AF4-63E8-4AE6-84A0-2E4C5AE44D65Q36316643-35B36E2C-C276-402B-B82A-9A0BCE63240CQ36361515-96AD1D73-9290-4F18-99DC-46C6F26A948AQ36382681-F50B54E3-E7DA-40F3-B825-5B6C9521DA2CQ36563578-199909F7-FB1B-490C-8481-9EFDC55BD6D2Q36640327-1E2B215A-2DDB-4A64-8F0A-2CBF1D0EC572Q36762858-DA346D73-C348-460F-80ED-6976FF92E7D7Q36782409-75B32058-AF54-4B16-A1C1-01435B501E00Q36900522-131031DF-A93D-44F6-B45F-2ECE53B7F777Q36967905-92BD260A-79EA-4540-90EB-4CDC6861DD7FQ36997524-E0790BE9-1B30-4DC3-A202-456241090FE6Q37223549-241B9B1B-DCCC-4FB2-A21A-E79AC34F6960Q37265126-E40EE83F-B6F1-46C8-A6F6-8D8848E2B11EQ37353968-CE702575-F098-453A-B9DD-80EFE59A1BB8
P2860
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Preclinical pharmacology of AZ ...... ivity with genetic background.
@ast
Preclinical pharmacology of AZ ...... ivity with genetic background.
@en
Preclinical pharmacology of AZ ...... ivity with genetic background.
@nl
type
label
Preclinical pharmacology of AZ ...... ivity with genetic background.
@ast
Preclinical pharmacology of AZ ...... ivity with genetic background.
@en
Preclinical pharmacology of AZ ...... ivity with genetic background.
@nl
altLabel
Preclinical pharmacology of AZ ...... tivity with genetic background
@en
prefLabel
Preclinical pharmacology of AZ ...... ivity with genetic background.
@ast
Preclinical pharmacology of AZ ...... ivity with genetic background.
@en
Preclinical pharmacology of AZ ...... ivity with genetic background.
@nl
P2093
P3181
P1476
Preclinical pharmacology of AZ ...... ivity with genetic background.
@en
P2093
Barry R Davies
Beirong Gao
Christine C Chresta
Claire Crafter
Clare Lane
Darren Cross
Donald Ogilvie
Hannah Greenwood
James Yates
P304
P3181
P356
10.1158/1535-7163.MCT-11-0824-T
P407
P577
2012-04-01T00:00:00Z